Search

Author/Creator Shore, Neal D

1. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Issue 2 (February 2015)

Authors:
Ryan, Charles J; Smith, Matthew R; Fizazi, Karim; Saad, Fred; Mulders, Peter F A; Sternberg, Cora N; Miller, Kurt; Logothetis, Christopher J; Shore, Neal D; Small, Eric J; Carles, Joan; Flaig, Thomas W; Taplin, Mary-Ellen; Higano, Celestia S; de Souza, Paul; de Bono, Johann S; Griffin, Thomas W; ...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 2(2015:Feb.)
Page Start:
152
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Issue 2 (February 2015)

Authors:
Ryan, Charles J; Smith, Matthew R; Fizazi, Karim; Saad, Fred; Mulders, Peter F A; Sternberg, Cora N; Miller, Kurt; Logothetis, Christopher J; Shore, Neal D; Small, Eric J; Carles, Joan; Flaig, Thomas W; Taplin, Mary-Ellen; Higano, Celestia S; de Souza, Paul; de Bono, Johann S; Griffin, Thomas W; ...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 2(2015:Feb.)
Page Start:
152
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Issue 2 (February 2016)

Authors:
Shore, Neal D; Chowdhury, Simon; Villers, Arnauld; Klotz, Laurence; Siemens, D Robert; Phung, De; van Os, Steve; Hasabou, Nahla; Wang, Fong; Bhattacharya, Suman; Heidenreich, Axel
Journal:
Lancet oncology
Issue:
Volume 17:Issue 2(2016:Feb.)
Page Start:
153
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Issue 1 (January 2021)

Authors:
Boorjian, Stephen A; Alemozaffar, Mehrdad; Konety, Badrinath R; Shore, Neal D; Gomella, Leonard G; Kamat, Ashish M; Bivalacqua, Trinity J; Montgomery, Jeffrey S; Lerner, Seth P; Busby, Joseph E; Poch, Michael; Crispen, Paul L; Steinberg, Gary D; Schuckman, Anne K; Downs, Tracy M; Svatek, Robert S...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 1(2021)
Page Start:
107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. (8th February 2018)

Authors:
Flanders, Scott C; Kim, Janet; Wilson, Samuel; Braziunas, Jeffrey; Greenfield, Sheldon; Billimek, John; Lechpammer, Stanislav; Lin, Daniel W; Karsh, Lawrence; Quinn, David I; Shevrin, Daniel; Shore, Neal D; Symanowski, James T; Penson, David F
Journal:
Future oncology
Issue:
Volume 14:Number 6(2018)
Page Start:
527
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗